Reliance-owned Strand Life Sciences develops prenatal genomic diagnostics portfolio
Reliance Industries Ltd.'s Strand Life Sciences has unveiled two ground-breaking prenatal screening and diagnostic technologies: MaatriSeq (non-invasive prenatal screening) and CNSeq (aneuploidy detection). These technologies, which offer unmatched efficiency, cost-effectiveness, and precision, are specifically designed to meet the needs of the Indian population. Using proprietary software, CNSeq outperforms conventional cytogenetic and molecular approaches in identifying Copy Number Variations (CNVs) with unparalleled precision. MaatriSeq is the first Non-Invasive Prenatal Screening (NIPS) solution that has been validated on the newest Illumina high-throughput NovaSeqTM X Plus sequencing platform. This means that a larger community in India can now have access to a highly accurate and affordable option. The mission of Strand Life Sciences is to support the Indian government's initiatives to lessen the prevalence of rare diseases in the country.